SynthesisCurrent urology reports2022
The Use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Diagnostic and Prognostic Biomarker in Urinary Tract Obstruction: a Systematic Review.
Synthesis in Current urology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Diagnostic Value of Serum Neutrophil Gelatinase-Associated Lipocalin for Adrenal Insufficiency.Chonnam medical journal · 2026Article
- Acute kidney injury in urological conditions.Asian biomedicine : research, reviews and news · 2026Review
- A Bibliometric Analysis of Research Trends in Paediatric Pelvic-Ureteric Junction Obstruction.Cureus · 2025Review
- Comparative analysis of ureteroileal anastomotic stricture rates: Bricker versus Wallace techniques in ileal conduit urinary diversion-a single-surgeon study with BMI-matched design and long-term follow-up excluding cancer recurrence bias.Frontiers in oncology · 2025Article
- The diagnostic accuracy of urinary neutrophil gelatinase-associated lipocalin in assessing kidney function in severe hydronephrosis.Translational andrology and urology · 2024Article
- Silencing HE4 alleviates the renal fibrosis in lupus nephritis mice by regulating the C3/MMPs/prss axis.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions.International journal of molecular sciences · 2023Article
- Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe early recognition of urinary tract obstruction (UTO) is vital in order to prevent mortality and morbidity associated with an acute kidney injury (AKI) and progression to irreversible kidney damage. Urinary biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) have been recognised as an accurate tool in the timely diagnosis of AKI, but its role in the detection, prognosis and subsequent monitoring of a variety of obstructive uropathies has not yet been explored. We performed a systematic review of literature in accordance with Cochrane methodology from inception to August 2021. RECENT
findingsEleven studies were included in which urine and serum NGAL were measured (616 patients) presenting with multiple UTO aetiologies. Four investigated kidney stone disease (KSD) exclusively, whilst other studies identified other causes of UTO including pelviureteric junction obstruction (PUJO), retroperitoneal fibrosis (RPF) and ureteric strictures. Six studies monitored NGAL levels after surgical intervention to relieve the obstruction. Nine studies demonstrated a significant increase in both urine and serum NGAL levels in UTO, often in a more sensitive and timely manner than serum creatinine. Subclinical unilateral UTO could be recognised by urinary NGAL levels even in the absence of changes in serum creatinine. Following surgical intervention, a reduction in urinary and serum NGAL was seen in all but two studies. NGAL levels decreased acutely by 14% in 2 h and showed a long-term reduction of 78% in 6 months. Readily available but not yet widely accepted, NGAL has the potential to be a less invasive, low-cost diagnostic test for urinary tract obstructions as a whole. Not only can it be used as a marker of treatment success but also to monitor for obstruction recurrence or progression. Further research is required to acknowledge urinary biomarkers such as NGAL as a potential replacement to standard renal function monitoring tests in the context of obstructive uropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.